Wells Fargo
AVIR icon

Wells Fargo’s Atea Pharmaceuticals AVIR Stock Holding History

Wells Fargo’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
59,716
+32,947
+123% +$164K ﹤0.01% 4986
2026
Q1 		$144K Sell
26,769
-53,025
-66% -$244K ﹤0.01% 4904
2025
Q4 		$285K Buy
79,794
+20,921
+36% +$66.5K ﹤0.01% 4866
2025
Q3 		$171K Buy
58,873
+9,584
+19% +$32.7K ﹤0.01% 5014
2025
Q2 		$177K Buy
49,289
+2,875
+6% +$8.57K ﹤0.01% 4838
2025
Q1 		$139K Buy
46,414
+1,023
+2% +$3.19K ﹤0.01% 4917
2024
Q4 		$152K Buy
45,391
+9,865
+28% +$32.8K ﹤0.01% 4956
2024
Q3 		$119K Buy
35,526
+1,172
+3% +$4.25K ﹤0.01% 4914
2024
Q2 		$114K Buy
34,354
+6,815
+25% +$25.4K ﹤0.01% 4857
2024
Q1 		$111K Buy
27,539
+3,475
+14% +$13.6K ﹤0.01% 4827
2023
Q4 		$73.4K Buy
24,064
+4,612
+24% +$14K ﹤0.01% 5097
2023
Q3 		$58.4K Sell
19,452
-10,249
-35% -$34.9K ﹤0.01% 5102
2023
Q2 		$111K Buy
29,701
+15,637
+111% +$58.5K ﹤0.01% 4974
2023
Q1 		$47.1K Buy
14,064
+13,564
+2,713% +$55K ﹤0.01% 5187
2022
Q4 		$2.4K Sell
500
-195
-28% -$986 ﹤0.01% 5966
2022
Q3 		$4K Sell
695
-622
-47% -$4.76K ﹤0.01% 5958
2022
Q2 		$10K Sell
1,317
-29,016
-96% -$198K ﹤0.01% 5738
2022
Q1 		$219K Sell
30,333
-21,430
-41% -$146K ﹤0.01% 4930
2021
Q4 		$463K Sell
51,763
-229,956
-82% -$3.58M ﹤0.01% 4720
2021
Q3 		$9.88M Buy
281,719
+281,441
+101,238% +$7.81M ﹤0.01% 2226
2021
Q2 		$6K Sell
278
-4,288
-94% -$129K ﹤0.01% 6271
2021
Q1 		$282K Sell
4,566
-2,996
-40% -$202K ﹤0.01% 4998
2020
Q4 		$316K Buy
+7,562
New +$244K ﹤0.01% 4847

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's AVIR Position: Q2 2026 in Review

Wells Fargo increased its Atea Pharmaceuticals (AVIR) stake by 123% in Q2 2026, buying an estimated $164K and bringing the position to 59,716 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #4986.

Wells Fargo first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $9.88M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Wells Fargo held 59,716 shares of Atea Pharmaceuticals worth $278K as of Q2 2026.
  • Wells Fargo bought 32,947 Atea Pharmaceuticals shares in Q2 2026, an estimated $164K.
  • Atea Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4986 holding.
  • Wells Fargo first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Wells Fargo's Atea Pharmaceuticals position peaked at $9.88M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.